Chenhui Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chenhui Cao has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Chuan Xu
Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, China
53 shared publications - Haitao Lan
Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, P. R. China
48 shared publications - Hang Zhou
Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, P. R. China
48 shared publications - Hong Wu
Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, PR China
48 shared publications - Lanlin Hu
Yu-Yue Pathology Scientific Research Center, Chongqing 400039, China
48 shared publications - Liang Chen
University of Science and Technology of China
48 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1971472
Preoperative systemic immunothrombotic state class is associated with microvascular invasion and early recurrence after curative resection for hepatocellular carcinoma
Background: Microvascular invasion (MVI) and early recurrence limit durable benefit after curative resection for hepatocellular carcinoma (HCC). We assessed whether an outcome-blinded preoperative systemic immunothrombotic state was associated with pathological MVI and 24-month recurrence and examined NET-associated circulating and tissue markers. Methods: This observational cohort included 520 patients undergoing curative-intent HCC resection. Three systemic immunothrombotic state classes were derived without outcome information from six preoperative immune-coagulation components; a continuous principal-component burden score was examined supportively. MVI was evaluated using multivariable logistic regression with 30-fold multiple imputation. Twenty-four-month recurrence was analyzed using Fine-Gray competing-risk models, treating death without recurrence as a competing event. Circulating H3Cit and MPO-DNA were measured in 302 patients with valid paired assays. A balanced nested tissue subset of 72 patients selected by state class and MVI status underwent quantitative H3Cit/MPO and CD8 spatial assessment. Results: High versus low state class was associated with MVI (OR 2.51, 95% CI 1.42–4.43; P = 0.002) and 24-month recurrence (sHR 1.87, 95% CI 1.28–2.74; P = 0.001), whereas the intermediate class was not significantly associated with either outcome. The continuous burden score showed supportive associations with both outcomes. Circulating H3Cit and MPO-DNA increased across state classes, but neither was independently associated with MVI after multivariable adjustment. In the tissue subset, high state class was associated with greater peritumoral and intratumoral H3Cit/MPO-positive density. Circulating H3Cit remained associated with peritumoral H3Cit/MPO density after adjustment for state class, MVI, and age, whereas corresponding MPO-DNA and intratumoral associations were weaker. CD8 spatial exclusion did not differ significantly by state class. Conclusion: A high preoperative systemic immunothrombotic state was associated with pathological MVI and 24-month recurrence after HCC resection. The clearest blood-tissue concordance involved circulating H3Cit and peritumoral H3Cit/MPO density. The state class added only modest internal discrimination, supporting external validation before clinical application and further mechanistic work to define the role of NET-associated activity.
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1971472
Open AccessPreoperative systemic immunothrombotic state class is associated with microvascular invasion and early recurrence after curative resection for hepatocellular carcinoma
Background: Microvascular invasion (MVI) and early recurrence limit durable benefit after curative resection for hepatocellular carcinoma (HCC). We assessed whether an outcome-blinded preoperative systemic immunothrombotic state was associated with pathological MVI and 24-month recurrence and examined NET-associated circulating and tissue markers. Methods: This observational cohort included 520 patients undergoing curative-intent HCC resection. Three systemic immunothrombotic state classes were derived without outcome information from six preoperative immune-coagulation components; a continuous principal-component burden score was examined supportively. MVI was evaluated using multivariable logistic regression with 30-fold multiple imputation. Twenty-four-month recurrence was analyzed using Fine-Gray competing-risk models, treating death without recurrence as a competing event. Circulating H3Cit and MPO-DNA were measured in 302 patients with valid paired assays. A balanced nested tissue subset of 72 patients selected by state class and MVI status underwent quantitative H3Cit/MPO and CD8 spatial assessment. Results: High versus low state class was associated with MVI (OR 2.51, 95% CI 1.42–4.43; P = 0.002) and 24-month recurrence (sHR 1.87, 95% CI 1.28–2.74; P = 0.001), whereas the intermediate class was not significantly associated with either outcome. The continuous burden score showed supportive associations with both outcomes. Circulating H3Cit and MPO-DNA increased across state classes, but neither was independently associated with MVI after multivariable adjustment. In the tissue subset, high state class was associated with greater peritumoral and intratumoral H3Cit/MPO-positive density. Circulating H3Cit remained associated with peritumoral H3Cit/MPO density after adjustment for state class, MVI, and age, whereas corresponding MPO-DNA and intratumoral associations were weaker. CD8 spatial exclusion did not differ significantly by state class. Conclusion: A high preoperative systemic immunothrombotic state was associated with pathological MVI and 24-month recurrence after HCC resection. The clearest blood-tissue concordance involved circulating H3Cit and peritumoral H3Cit/MPO density. The state class added only modest internal discrimination, supporting external validation before clinical application and further mechanistic work to define the role of NET-associated activity.
- Open Access
- 21 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1744925
Treatment outcomes and next-generation sequencing of a rare malignancy - urachal carcinoma: case report and literature review
UrC is a rare malignancy with uncertain pathogenesis. The main symptoms include gross hematuria, abdominal pain, and an abdominal mass. The lack of comprehensive clinical analysis necessitates selecting an optimal therapeutic strategy for each patient. Here, we present a comprehensive review of the clinical manifestations, diagnosis, and treatment of UrC, illustrated with a case successfully managed through surgical intervention and adjuvant chemoradiotherapy. Meanwhile, the analysis of NGS detected two tumor-specific mutated genes: MYC (gene amplification, CN: 59.5) and FLT1 (missense mutation, c.1061G>A (p.R354Q), abundance: 2.1%). These findings may provide insights into tumor growth and guide therapeutic strategies.
- 21 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1744925
Open AccessTreatment outcomes and next-generation sequencing of a rare malignancy - urachal carcinoma: case report and literature review
UrC is a rare malignancy with uncertain pathogenesis. The main symptoms include gross hematuria, abdominal pain, and an abdominal mass. The lack of comprehensive clinical analysis necessitates selecting an optimal therapeutic strategy for each patient. Here, we present a comprehensive review of the clinical manifestations, diagnosis, and treatment of UrC, illustrated with a case successfully managed through surgical intervention and adjuvant chemoradiotherapy. Meanwhile, the analysis of NGS detected two tumor-specific mutated genes: MYC (gene amplification, CN: 59.5) and FLT1 (missense mutation, c.1061G>A (p.R354Q), abundance: 2.1%). These findings may provide insights into tumor growth and guide therapeutic strategies.
- Open Access
- 24 November 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (24) , 3351-3380
Ferroptosis: A new horizon in cancer therapy
Ferroptosis is an iron-catalyzed form of regulated cell death mediated by lipid peroxidation. Novel ferroptosis-based therapeutic strategies could selectively target core pathways associated with the proliferation and survival of malignant tumors, not only directly inducing tumor cell death but also overcoming resistance to conventional therapies, paving a new path for precision cancer treatment. Ferroptosis suppresses tumor progression through lethal lipid peroxidation, yet is co-opted by cancers through antioxidant adaptations. This review highlights the dual role of ferroptosis in tumor biology and explores the dynamic interplay between ferroptosis and the tumor microenvironment to modulate both immunogenic cell death and immunosuppressive signaling. We discuss the therapeutic potential of ferroptosis induction through synergistic integration with chemotherapy, targeted therapy, radiotherapy, hyperthermia therapy, and immunotherapy to simultaneously suppress tumor progression, overcome resistance mechanisms, and potentiate antitumor immunity, thereby offering innovative strategies to address treatment-refractory malignancies. Challenges include identifying predictive biomarkers, developing tumor-selective ferroptosis inducers, and modulating ferroptosis–immune interactions within the tumor microenvironment. By addressing these issues, ferroptosis has the potential to overcome treatment-resistant and immune-evasive tumors, reshaping oncology therapeutics.
- 24 November 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (24) , 3351-3380
Open AccessFerroptosis: A new horizon in cancer therapy
Ferroptosis is an iron-catalyzed form of regulated cell death mediated by lipid peroxidation. Novel ferroptosis-based therapeutic strategies could selectively target core pathways associated with the proliferation and survival of malignant tumors, not only directly inducing tumor cell death but also overcoming resistance to conventional therapies, paving a new path for precision cancer treatment. Ferroptosis suppresses tumor progression through lethal lipid peroxidation, yet is co-opted by cancers through antioxidant adaptations. This review highlights the dual role of ferroptosis in tumor biology and explores the dynamic interplay between ferroptosis and the tumor microenvironment to modulate both immunogenic cell death and immunosuppressive signaling. We discuss the therapeutic potential of ferroptosis induction through synergistic integration with chemotherapy, targeted therapy, radiotherapy, hyperthermia therapy, and immunotherapy to simultaneously suppress tumor progression, overcome resistance mechanisms, and potentiate antitumor immunity, thereby offering innovative strategies to address treatment-refractory malignancies. Challenges include identifying predictive biomarkers, developing tumor-selective ferroptosis inducers, and modulating ferroptosis–immune interactions within the tumor microenvironment. By addressing these issues, ferroptosis has the potential to overcome treatment-resistant and immune-evasive tumors, reshaping oncology therapeutics.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Table S5 shows sequences of the primers used for qRT-PCR.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Table S5 shows sequences of the primers used for qRT-PCR.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Figure S8 shows intra-tumoral bacterial contents were stable during tumor growth.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Figure S8 shows intra-tumoral bacterial contents were stable during tumor growth.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Figure S7 shows fecal microbial transplantation (FMT) influenced the immune microenvironment of subcutaneous xenograft tumor tissues.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Figure S7 shows fecal microbial transplantation (FMT) influenced the immune microenvironment of subcutaneous xenograft tumor tissues.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Table S4 shows reagents and antibodies.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Table S4 shows reagents and antibodies.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Table S3 shows clinical characteristics of feces providers for fecal microbiota transplantation.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Intratumoral Microbiota Composition Regulates Chemoimmunotherapy Response in Esophageal Squamous Cell Carcinoma
Table S3 shows clinical characteristics of feces providers for fecal microbiota transplantation.